für Erwachsene - Jahr 2010
Adult Immunization Schedule
United States, 2010
The Advisory Committee on Immunization Practices (ACIP) annually
reviews the recommended Adult Immunization Schedule to ensure
that the schedule reflects current recommendations for the licensed
vaccines. In October 2009, ACIP approved the Adult Immunization
Schedule for 2010, which includes several changes. A bivalent
human papillomavirus vaccine (HPV2) was licensed for use in
females in October 2009. ACIP recommends vaccination of females
with either HPV2 or the quadrivalent human papillomavirus vaccine
(HPV4). HPV4 was licensed for use in males in October 2009,
and ACIP issued a permissive recommendation for use in males.
Introductory sentences were added to the footnotes for measles,
mumps, rubella, influenza, pneumococcal, hepatitis A, hepatitis
B, and meningococcal vaccines. Clarifications were made to the
footnotes for measles, mumps, rubella, influenza, hepatitis
A, meningococcal, and Haemophilus influenza type
b vaccines, and schedule information was added to the hepatitis
B vaccine footnote.
Additional information is available
as follows: schedule (in English and Spanish)
adult vaccination at http://www.cdc.gov/vaccines/default.htm;
ACIP statements for specific
vaccines at http://www.cdc.gov/vaccine/pubs/acip-list.htm;
and reporting adverse events at http://www.vaers.hhs.gov or
Footnotes (Figures 1 and 2)
human papillomavirus (HPV) footnote (#2)
includes language that a bivalent HPV vaccine (HPV2) has
been licensed for use in females. Either HPV2 or the quadrivalent
human papillomavirus vaccine (HPV4) can be used for vaccination
of females aged 19 through 26 years. In addition, language
has been added to indicate that ACIP issued a permissive
recommendation for use of HPV4 in males.
measles, mumps, rubella (MMR) footnote
(#5) has language added to clarify which adults born during
or after 1957 do not need 1 or more doses of MMR vaccine
for the measles and mumps components, and clarifies which
women should receive a dose of MMR vaccine. Also, interval
dosing information has been added to indicate when a second
dose of MMR vaccine should be administered. Language has
been added to highlight recommendations for vaccinating
health-care personnel born before 1957 routinely and during
term “seasonal” has been added
to the influenza footnote (#6).
hepatitis A footnote (#9) has language
added to indicate that unvaccinated persons who anticipate
close contact with an international adoptee should consider
hepatitis B footnote (#10) has language
added to include schedule information for the 3-dose hepatitis
meningococcal vaccine footnote (#11) clarifies
which vaccine formulations are preferred for adults aged
≤55 years and ≥56 years, and which vaccine formulation
can be used for revaccination. New examples have been added
to demonstrate who should and should not be considered for
The selected conditions for Haemophilus influenza type
b (Hib) footnote (#13) clarifies which high-risk
persons may receive 1 dose of Hib vaccine.
The Recommended Adult Immunization Schedule has been approved
by the Advisory Committee on Immunization Practices, the American
Academy of Family Physicians, the American College of Obstetricians
and Gynecologists, and the American College of Physicians.
Suggested citation: Centers for Disease Control and
Prevention. Recommended adult immunization schedule---United
States, 2010. MMWR 2010;59(1).
1. Recommended adult immunization schedule, by vaccine
and age group - United States, 2010
figure above shows the recommended adult immunization schedule,
by vaccine and age group for the United States in 2010.
2. Vaccines that might be indicated for adults, based
on medical and other indications - United States, 2010
figure above shows vaccines that might be indicated for adults,
based on medical and other indications in the United States
schedules indicate the recommended age groups and medical
indications for which administration of currently licensed
vaccines is commonly indicated for adults aged >19
years, as of January 1, 2009. Licensed combination vaccines
may be used whenever any components of the combination are
indicated and when the vaccine’s other components are
not contraindicated. For detailed recommendations on all vaccines,
including those that are used primarily for travelers or are
issued during the year, consult the manufacturers’ package
inserts and the complete statements from the Advisory Committee
on Immunization Practices (ACIP) (http://www.cdc.gov/vaccines/pubs/acip-list.htm).
Report all clinically significant postvaccination reactions
to the Vaccine Adverse Event Reporting System (VAERS). Reporting
forms and instructions on filing a VAERS report are available
at http://www.vaers.hhs.gov or
by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program
claim is available at http://www.hrsa.gov/vaccinecompensation or
by telephone, 800-338-2382. To file a claim for vaccine injury,
contact the U.S. Court of Federal Claims, 717 Madison Place,
N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule,
extent of available data, and contraindications for vaccination
is available at http://www.cdc.gov/vaccines or
from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636)
in English and Spanish, 24 hours a day, 7 days a week.
Use of trade names and commercial sources is for identification
only and does not imply endorsement by the U.S. Department
of Health and Human Services.
The recommendations in this schedule were approved by ACIP,
the American Academy of Family Physicians, the American College
of Obstetricians and Gynecologists, and the American College
Department of Health and Human Services • Centers for
Disease Control and Prevention